Clinical Trials Directory

Trials / Terminated

TerminatedNCT04643535

In Vivo Glycocalyx as Predictor of Complications After Cardiac Surgery

Glycocalyx as Predictor of Complications After Cardiac Surgery

Status
Terminated
Phase
Study type
Observational
Enrollment
130 (actual)
Sponsor
University Hospital, Rouen · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Cardiac surgery has been described as altering endothelium structure and function, notably because of the use of cardiac-pulmonary bypass (CPB). Among the endothelial structure, glycocalyx, the thin layer recovering the endothelial surface, may be altered by the inflammatory process and probably the modification of flow during CPB. Endothelial and glycocalyx integrity are essential for vascular function and glycocalyx destruction is associated with organ failure and mortality. On the other hand, a chronic alteration of glycocalyx is observed in many diseases such as diabetes, hypertension or chronic kidney failure, all pathologies frequently observed in patients benefiting grom cardiac surgery. Thus the preoperative alteration of glycocalyx may be associated with postoperative organ failure.

Conditions

Timeline

Start date
2020-11-30
Primary completion
2024-07-03
Completion
2025-12-30
First posted
2020-11-25
Last updated
2026-02-18

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04643535. Inclusion in this directory is not an endorsement.

In Vivo Glycocalyx as Predictor of Complications After Cardiac Surgery (NCT04643535) · Clinical Trials Directory